References
- Pizzo PA. Management of fever in patients with cancer and treatment-induced neutropenia. N Engl J Med 1993; 328: 1323–32.
- Wynd MA, Paladino JA. Cefepime: a fourth-generation parenteral cephalosporin. Ann Pharmacother 1996; 30: 1414–24.
- Barradell LB, Bryson HM. Cefepime: a review of its antibacterial activity, pharmacokinetic properties and therapeutic use. Drugs 1994; 47: 471–505.
- Hughes WT, Pizzo PA, Wade JC, Armstrong D, Webb CD, Young LS. Evaluation of new anti-infective drugs for the treatment of febrile episodes in neutropenic patients. Infectious Diseases Society of America and the Food and Drug Administration. Clin Infect Dis 1992; 15 (Suppl.1): 206–15.
- Hughes WT, Armstrong D, Bodey GP, Brown AE, Edwards JE, Feld R, et al. Guidelines for the use of antimicrobial agents in neutropenic patients with unexplained fever. Clin Infect Dis 1997; 25: 551–73.
- Cordonnier C, Herbrecht R, Pico JL, Gardembas M, Delmer A, Delain M, et al. Cefepime/amikacin versus ceftazidime/amikacin as empirical therapy for febrile episodes in neutropenic patients: A comparative study. Clin Infect Dis 1997; 24: 41–51.
- Akova M, Hayran M, Uzun Ö, Ünal S, Kars A, Kansu E, et al. Prognostic factors determining the outcome of empirical antibacterial treatment in neutropenic cancer patients with fever. Program and abstracts of the 35th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, CA. Washington, D.C.: American Society for Microbiology, 1995: 262 [Abstract 87].
- Pizzo PA, Hathorn JW, Hiemenz JW, Browne M, Commers J, Cotton D, et al. A randomized trial comparing ceftazidime alone with combination antibiotic therapy in cancer patients with fever and neutropenia. N Engl J Med 1986; 315: 552–8.
- Eggiman P, Glauser MP, Aoun M, Meunier F, Calandra T. Cefepime monotherapy for the empirical treatment of fever in granulocytopenic cancer patients. J Antimicrob Chemother 1993; 32 (Suppl B): 151–63.
- Ramphal R, Gucalp R, Rotstein C, Cimino M, Oblon D. Clinical experience with single agent and combination regimens in the management of infection in the febrile neutropenic patient. Am J Med 1996; 100 (Suppl 6A): S83–9.
- Chandrasekar PH, Arnow PM. Cefepime versus ceftazidime as empiric therapy for fever in neutropenic patients with cancer. Ann Pharmacother 2000; 34: 989–95.
- Biron P, Fuhrmann C, Cure H, Viens P, Lefebvre D, Thyss A, et al. Cefepime versus imipenem-cilastatin as empirical monotherapy in 400 febrile patients with short duration neutropenia. CEMIC (Study Group of Infectious Diseases in Cancer). J Antimicrob Chemother 1998; 42: 511–8.
- Bohme A, Shah PM, Stille W, Hoelzer D. Piperacillin-tazobactam versus cefepime as initial empirical antimicrobial therapy in febrile neutropenic patients: a prospective randomized pilot study. Eur J Med Res 1998; 3: 324–30.
- Yamamura D, Gucalp R, Carlisle P, Cimino M, Roberts J, Rotstein C. Open randomized study of cefepime versus piperacillin-gentamicin for treatment of febrile neutropenic patients. Antimicrob Agents Chemother 1997; 41: 1704–8.
- Oppenheim BA. The changing pattern of infection in neutropenic patients. J Antimicrob Chemother 1998; 41 (Suppl D): 7–11.
- Akova M, Hayran M, Ünal S, Gür D, Uzun Ö, Kars A, et al. Characteristics of infectious agents in adult cancer patients with neutropenia and fever. Abstracts of the 13th Meeting of the International Society of Haematology, Istanbul, Turkey 3–8 September, 1995 [Abstract 255].
- Akova M, Akan H, Korten V, Biberoglu K, Hayran M, Unal S, et al. Comparison of meropenem with amikacin plus ceftazidime in the empirical treatment of febrile neutropenia: a prospective randomised multicentre trial in patients without previous prophylactic antibiotics. Int J Antimicrob Agents 1999; 13: 15–9.